Quanterix price to book ratio QTRX
Market value divided by the book value of the company's net assets, since 2018.
- Today, Oct 23, 2026
- 0.6×
- 8-year median
- 2.5×
- Against its 8-year history
- 4th
- percentile: 0 is its lowest day, 100 its highest
- 8-year range
- 0.4× to 22.5×
- Peer median
- 2.5×
Quanterix's price to book ratio is 0.6× as of Oct 23, 2026.
That is below its 8-year median of 2.5×, lower than on 96% of days in the last 8 years.
Over that time it ranged from 0.4× in May 2026 to 22.5× in Jun 2019.
The median for 10 healthcare stocks of a similar size is 2.5×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 0.6× | 0.4× | 1.2× |
| 2025 | 1.0× | 0.6× | 1.4× |
| 2024 | 1.3× | 1.2× | 3.0× |
| 2023 | 2.9× | 1.1× | 2.9× |
| 2022 | 1.4× | 0.8× | 2.8× |
| 2021 | 3.4× | 3.0× | 13.7× |
| 2020 | 7.0× | 3.1× | 11.8× |
| 2019 | 4.8× | 4.7× | 22.5× |
| 2018 | 8.5× | 5.3× | 9.1× |
Against its peers
Companies in Healthcare nearest Quanterix's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| QTRXQuanterix | 0.6× |
| KEQUKewaunee Scientific | 1.3× |
| ICCCImmucell | 3.0× |
| PDEXPro DEX | 4.2× |
| PLXProtalix BioTherapeutics | 2.9× |
| NATRNatures Sunshine Products | 1.3× |
| ELMDElectromed | 4.1× |
| UTMDUtah Medical Products | 1.9× |
| LFVNLifevantage | 2.2× |
| INFUInfuSystem | 4.7× |
| SPROSpero Therapeutics | 1.5× |
| Peer median | 2.5× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Quanterix
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.